Infant Bacterial Therapeutics AB OMXSTO:IBT_B:
Q3 NET SALES SEK 0 THOUSAND
Q3 OPERATING PROFIT SEK -48,457 THOUSAND
Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
Infant Bacterial Therapeutics AB on 6ix
Earlier from Infant Bacterial Therapeutics
- Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3
- IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify
- IBT_B: FDA Breakthrough Therapy Designation for IBP-9414 accelerates IBT's market path
- IBT_B: IBP-9414's Phase 3 trial showed 27% lower mortality; BLA submission planned for 2025
- IBT_B: Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push
Later from Infant Bacterial Therapeutics
- Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Substance
- Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Product
- Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln
- Infant Bacterial Announces Phase III IBP-9414 Study Results
- Infant Bacterial Therapeutics AB publishes the Annual Report for 2025
Follow Infant Bacterial Therapeutics into a list and get an email when it puts out news.
Follow Infant Bacterial Therapeutics